

Gregory S Merrick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7508221/publications.pdf>

Version: 2024-02-01

153
papers

6,117
citations

53794

45
h-index

79698

73
g-index

153
all docs

153
docs citations

153
times ranked

3146
citing authors

#	ARTICLE	IF	CITATIONS
1	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, e216871.	7.1	18
2	ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 249-257.	1.3	1
3	The impact of age on prostate cancer progression and quality of life in active surveillance patients. <i>BJUI Compass</i> , 2021, 2, 86-91.	1.3	3
4	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	5.9	12
5	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021, 80, 142-146.	1.9	12
6	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. <i>Brachytherapy</i> , 2021, 20, 1114-1129.	0.5	26
7	Effect of the timing of hydrogel spacer placement on prostate and rectal dosimetry of low-dose-rate brachytherapy implants. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 145-151.	0.9	5
8	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€‘Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	5.9	18
9	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020, 77, 3-10.	1.9	18
10	Active surveillance outcomes in prostate cancer patients: the use of transperineal template-guided mapping biopsy for patient selection. <i>World Journal of Urology</i> , 2020, 38, 361-369.	2.2	3
11	The narrow door of success. <i>Brachytherapy</i> , 2020, 19, 1-5.	0.5	4
12	Associations of multimorbidity and patientâ€‘reported experiences of care with conservative management among elderly patients with localized prostate cancer. <i>Cancer Medicine</i> , 2020, 9, 6051-6061.	2.8	2
13	A biochemical definition of cure after brachytherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 149, 64-69.	0.6	48
14	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 896.	7.4	252
15	Location and Grade of Prostate Cancer Diagnosed by Transperineal Template-guided Mapping Biopsy After Negative Transrectal Ultrasound-guided Biopsy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 723-729.	1.3	12
16	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 883-888.	0.8	10
17	Metformin Does Not Predict for Prostate Cancer Diagnosis, Grade, or Volume of Disease After Transperineal Template-guided Mapping Biopsy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 353-357.	1.3	2
18	Transperineal Template-guided Mapping Biopsy Identifies Pathologic Differences Between Veryâ€‘Low-risk and Low-risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 53-59.	1.3	9

#	ARTICLE	IF	CITATIONS
19	The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancer. <i>Brachytherapy</i> , 2017, 16, 59-67.	0.5	25
20	Incidence, grade and distribution of prostate cancer following transperineal template-guided mapping biopsy in patients with atypical small acinar proliferation. <i>World Journal of Urology</i> , 2017, 35, 1009-1013.	2.2	10
21	American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. <i>Brachytherapy</i> , 2017, 16, 1-12.	0.5	69
22	Does supplemental external beam radiation therapy impact urinary, bowel, and erectile function following permanent prostate brachytherapy?: results of two prospective randomized trials. <i>Journal of Contemporary Brachytherapy</i> , 2017, 5, 403-409.	0.9	6
23	Prostate cancer-specific death in brachytherapy treated high-risk patients stratified by pre-treatment PSA. <i>Journal of Contemporary Brachytherapy</i> , 2017, 4, 297-303.	0.9	1
24	Pathology and Quality of Life Outcomes Following Office-based Transperineal Prostate Biopsy. <i>Urology</i> , 2016, 94, 24-28.	1.0	10
25	Focal prostate brachytherapy with 103 Pd seeds. <i>Physica Medica</i> , 2016, 32, 459-464.	0.7	7
26	Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease?. <i>Brachytherapy</i> , 2016, 15, 79-84.	0.5	14
27	Diagnostic Performance of Initial Transperineal Template-guided Mapping Biopsy of the Prostate Gland. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 300-303.	1.3	18
28	Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts. <i>Journal of Contemporary Brachytherapy</i> , 2015, 6, 430-436.	0.9	9
29	Treatment outcomes with permanent brachytherapy in high-risk prostate cancer patients stratified into prognostic categories. <i>Brachytherapy</i> , 2015, 14, 766-772.	0.5	12
30	Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials. <i>Brachytherapy</i> , 2015, 14, 677-685.	0.5	21
31	Effect of metal hip prosthesis on the accuracy of electromagnetic localization tracking. <i>Practical Radiation Oncology</i> , 2015, 5, 43-48.	2.1	6
32	Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2014, 3, 254-261.	0.9	17
33	Multisector prostate dosimetric quality: Analysis of a large community database. <i>Brachytherapy</i> , 2014, 13, 146-151.	0.5	11
34	Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: Is the primary pattern on needle biopsy prognostic?. <i>Brachytherapy</i> , 2013, 12, 14-18.	0.5	14
35	Impact of small prostate size on postimplant prostate dosimetry: Analysis of a large community database. <i>Brachytherapy</i> , 2013, 12, 222-227.	0.5	4
36	Incidence and Pathological Features of Prostate Cancer Detected on Transperineal Template Guided Mapping Biopsy After Negative Transrectal Ultrasound Guided Biopsy. <i>Journal of Urology</i> , 2013, 190, 509-514.	0.4	59

#	ARTICLE	IF	CITATIONS
37	The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer. <i>Cancer</i> , 2013, 119, 681-690.	4.1	44
38	Time to failure after definitive therapy for prostate cancer: implications for importance of aggressive local treatment. <i>Journal of Contemporary Brachytherapy</i> , 2013, 4, 215-221.	0.9	10
39	Transperineal Template-guided Mapping Biopsy as a Staging Procedure to Select Patients Best Suited for Active Surveillance. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2013, 36, 116-120.	1.3	49
40	Permanent prostate brachytherapy extracapsular radiation dose distributions: analysis of a multi-institutional database. <i>Journal of Contemporary Brachytherapy</i> , 2013, 3, 117-121.	0.9	12
41	Intrafraction displacement of prone versus supine prostate positioning monitored by real-time electromagnetic tracking. <i>Journal of Applied Clinical Medical Physics</i> , 2013, 14, 198-208.	1.9	10
42	20 Gy Versus 44 Gy of Supplemental External Beam Radiotherapy With Palladium-103 for Patients With Greater Risk Disease: Results of a Prospective Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e449-e455.	0.8	15
43	Effect of Body Mass Index on Intrafraction Prostate Displacement Monitored by Real-Time Electromagnetic Tracking. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e173-e179.	0.8	10
44	American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. <i>Brachytherapy</i> , 2012, 11, 6-19.	0.5	399
45	Patient-reported long-term rectal function after permanent interstitial brachytherapy for clinically localized prostate cancer. <i>Brachytherapy</i> , 2012, 11, 341-347.	0.5	10
46	Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy. <i>Brachytherapy</i> , 2012, 11, 219-223.	0.5	0
47	Erectile dysfunction is predictive of all-cause mortality in patients with prostate cancer treated with permanent interstitial brachytherapy. <i>BJU International</i> , 2012, 109, 220-225.	2.5	3
48	The correlation between annular treatment margins and biochemical failure in prostate brachytherapy patients with optimized intraprostatic dosimetry. <i>Brachytherapy</i> , 2011, 10, 409-415.	0.5	5
49	The Incidence of Transition Zone Prostate Cancer Diagnosed by Transperineal Template-guided Mapping Biopsy: Implications for Treatment Planning. <i>Urology</i> , 2011, 77, 1148-1152.	1.0	34
50	Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 398-404.	1.6	2
51	The Effect of Pro-Qura Case Volume on Post-Implant Prostate Dosimetry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e727-e734.	0.8	4
52	Prostate cancer death is unlikely in high-risk patients following quality permanent interstitial brachytherapy. <i>BJU International</i> , 2011, 107, 226-232.	2.5	24
53	Long-Term Outcome for Clinically Localized Prostate Cancer Treated With Permanent Interstitial Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1336-1342.	0.8	144
54	Postimplant rectal dosimetry is not dependent on 103Pd or 125I seed activity. <i>Brachytherapy</i> , 2011, 10, 35-43.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Evaluation of radiobiologic biochemical control in a large permanent prostate brachytherapy population from a single institution using AAPM TG-137 parameters. <i>Brachytherapy</i> , 2011, 10, 16-28.	0.5	17
56	Comment on the "AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137" [<i>Med. Phys.</i> 36, 5310-5322 (2009)]. <i>Medical Physics</i> , 2010, 37, 404-404.	3.0	1
57	Whole-Pelvis Radiotherapy in Combination With Interstitial Brachytherapy: Does Coverage of the Pelvic Lymph Nodes Improve Treatment Outcome in High-Risk Prostate Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1078-1084.	0.8	28
58	Natural History of Clinically Staged Low- and Intermediate-Risk Prostate Cancer Treated With Monotherapeutic Permanent Interstitial Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 349-354.	0.8	65
59	Electromagnetic Tracking of Intrafraction Prostate Displacement in Patients Externally Immobilized in the Prone Position. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 490-495.	0.8	40
60	Greater Biopsy Core Number Is Associated With Improved Biochemical Control in Patients Treated With Permanent Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1104-1110.	0.8	6
61	Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapy. <i>BJU International</i> , 2010, 106, 809-814.	2.5	5
62	Analysis of the Pro-Qura Database: Rectal dose, implant quality, and brachytherapist's experience. <i>Brachytherapy</i> , 2009, 8, 34-39.	0.5	11
63	Erectile Function Durability Following Permanent Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 639-648.	0.8	50
64	Prostate cancer control and survival in Vietnam veterans exposed to Agent Orange. <i>Brachytherapy</i> , 2009, 8, 57-62.	0.5	4
65	A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients. <i>Medical Physics</i> , 2009, 36, 776-787.	3.0	18
66	Prebiopsy PSA Velocity Not Reliable Predictor of Prostate Cancer Diagnosis, Gleason Score, Tumor Location, or Cancer Volume After TTMB. <i>Urology</i> , 2009, 74, 171-176.	1.0	16
67	Influence of Pro-Qura-generated Plans on Postimplant Dosimetric Quality: A Review of a Multi-Institutional Database. <i>Medical Dosimetry</i> , 2008, 33, 206-214.	0.9	2
68	Prostate Brachytherapy in Men ≥ 75 Years of Age. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 415-420.	0.8	13
69	Primary Causes of Death After Permanent Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 433-440.	0.8	57
70	The morbidity of transperineal template-guided prostate mapping biopsy. <i>BJU International</i> , 2008, 101, 1524-1529.	2.5	93
71	Effects of the Time Interval Between Prostate Brachytherapy and Postimplant Dosimetric Evaluation in Community Practice. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 523-531.	1.3	5
72	Biochemical and Functional Outcomes Following Brachytherapy With or Without Supplemental Therapies in Men ≥ 50 Years of Age With Clinically Organ-Confined Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 539-544.	1.3	11

#	ARTICLE	IF	CITATIONS
73	Obesity Is Not Predictive of Overall Survival Following Permanent Prostate Brachytherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 588-596.	1.3	27
74	Long-Term Rectal Function After Permanent Prostate Brachytherapy. Cancer Journal (Sudbury, Mass), 2007, 13, 95-104.	2.0	22
75	Dosimetry of an Extracapsular Anulus Following Permanent Prostate Brachytherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 228-233.	1.3	19
76	Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer, 2007, 110, 289-296.	4.1	32
77	15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. International Journal of Radiation Oncology Biology Physics, 2007, 67, 57-64.	0.8	196
78	Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. International Journal of Radiation Oncology Biology Physics, 2007, 67, 342-346.	0.8	23
79	Androgen Deprivation Therapy Does Not Impact Cause-Specific or Overall Survival in High-Risk Prostate Cancer Managed With Brachytherapy and Supplemental External Beam. International Journal of Radiation Oncology Biology Physics, 2007, 68, 34-40.	0.8	48
80	Isotope and Patient Age Predict for PSA Spikes After Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1431-1437.	0.8	30
81	Prostate Cancer Distribution in Patients Diagnosed by Transperineal Template-Guided Saturation Biopsy. European Urology, 2007, 52, 715-724.	1.9	114
82	Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy, 2007, 6, 2-8.	0.5	47
83	Initial analysis of Pro-Qura: A multi-institutional database of prostate brachytherapy dosimetry. Brachytherapy, 2007, 6, 9-15.	0.5	35
84	Risk Factors for the Development of Prostate Brachytherapy Related Urethral Strictures. Journal of Urology, 2006, 175, 1376-1381.	0.4	80
85	Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology, 2006, 68, 116-120.	1.0	24
86	Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. BJU International, 2006, 97, 62-68.	2.5	52
87	Brachytherapy in men aged <= 54 years with clinically localized prostate cancer. BJU International, 2006, 98, 324-328.	2.5	35
88	Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2006, 65, 669-677.	0.8	62
89	Temporal relationship between prostate brachytherapy and the diagnosis of colorectal cancer. International Journal of Radiation Oncology Biology Physics, 2006, 66, 48-55.	0.8	11
90	Permanent prostate brachytherapy: is supplemental external-beam radiation therapy necessary?. Oncology, 2006, 20, 514-22; discussion 522-5.	0.5	13

#	ARTICLE	IF	CITATIONS
91	I-125 Versus Pd-103 for Low-Risk Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2005, 11, 385-389.	2.0	49
92	The Impact of Primary Gleason Grade on Biochemical Outcome Following Brachytherapy for Hormone-Naive Gleason Score 7 Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2005, 11, 234-240.	2.0	12
93	Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 32-43.	0.8	91
94	Erectile function after prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 437-447.	0.8	139
95	Rectal fistulas after prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 150-154.	0.8	72
96	Effect of post-implant edema on prostate brachytherapy treatment margins. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1469-1473.	0.8	27
97	The impact of radiation dose to the urethra on brachytherapy-related dysuria. <i>Brachytherapy</i> , 2005, 4, 45-50.	0.5	16
98	Variability of prostate brachytherapy preimplant dosimetry: A multi-institutional analysis. <i>Brachytherapy</i> , 2005, 4, 241-251.	0.5	49
99	Brachytherapy-related dysuria. <i>BJU International</i> , 2005, 95, 597-602.	2.5	26
100	Brachytherapy-associated erectile dysfunction. <i>Current Sexual Health Reports</i> , 2005, 2, 21-26.	0.8	2
101	20Gy versus 44Gy supplemental beam radiation with Pd-103 prostate brachytherapy: Preliminary biochemical outcomes from a prospective randomized multi-center trial. <i>Radiotherapy and Oncology</i> , 2005, 75, 307-310.	0.6	25
102	Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. <i>Urology</i> , 2005, 65, 95-100.	1.0	38
103	Prostate cryotherapy: More questions than answers. <i>Urology</i> , 2005, 66, 9-15.	1.0	26
104	Enzymatic prostatic acid phosphatase in the clinical staging of patients diagnosed with prostate cancer. <i>West Virginia Medical Journal</i> , 2005, 101, 116-9.	0.1	2
105	Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. <i>West Virginia Medical Journal</i> , 2005, 101, 168-71.	0.1	3
106	Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 81-88.	0.8	40
107	Influence of hormonal therapy on late rectal function after permanent prostate brachytherapy with or without supplemental external beam radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 68-74.	0.8	11
108	Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1056-1062.	0.8	25

#	ARTICLE	IF	CITATIONS
109	The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. <i>Brachytherapy</i> , 2004, 3, 22-29.	0.5	13
110	Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer. <i>Brachytherapy</i> , 2004, 3, 130-135.	0.5	21
111	Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation. <i>Brachytherapy</i> , 2004, 3, 141-146.	0.5	17
112	Medical malpractice of prostate brachytherapy. <i>Brachytherapy</i> , 2004, 3, 231-236.	0.5	18
113	Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer. <i>Urology</i> , 2004, 64, 754-759.	1.0	46
114	Permanent Interstitial Brachytherapy for Clinically Organ-Confined High-Grade Prostate Cancer With a Pretreatment PSA < 20 ng/mL. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 611-615.	1.3	12
115	Prognostic Significance of Percent Positive Biopsies in Clinically Organ Confined Prostate Cancer Treated with Permanent Prostate Brachytherapy With or Without Supplemental External Beam Radiation. <i>Cancer Journal (Sudbury, Mass)</i> , 2004, 10, 54-60.	2.0	18
116	Treatment Margins Predict Biochemical Outcomes After Prostate Brachytherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2004, 10, 175-180.	2.0	31
117	The Impact of Prostate Volume and Neoadjuvant Androgen-Deprivation Therapy on Urinary Function Following Prostate Brachytherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2004, 10, 181-189.	2.0	12
118	Rectal function following permanent prostate brachytherapy. <i>West Virginia Medical Journal</i> , 2004, 100, 18-20.	0.1	0
119	Patient selection for prostate brachytherapy: more myth than fact. <i>Oncology</i> , 2004, 18, 445-52; discussion 452, 455-7.	0.5	10
120	The dosimetry of brachytherapy-induced erectile dysfunction. <i>Medical Dosimetry</i> , 2003, 28, 271-274.	0.9	6
121	Dysuria after permanent prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 979-985.	0.8	50
122	Long-term urinary quality of life after permanent prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 454-461.	0.8	112
123	Late rectal function after prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 42-48.	0.8	41
124	125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 1297-1303.	0.8	120
125	Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy. <i>Brachytherapy</i> , 2003, 2, 181-188.	0.5	26
126	Rectal function following brachytherapy with or without supplemental external beam radiation: Results of two prospective randomized trials. <i>Brachytherapy</i> , 2003, 2, 147-157.	0.5	28

#	ARTICLE	IF	CITATIONS
127	Permanent Interstitial Brachytherapy for the Management of Carcinoma of the Prostate Gland. <i>Journal of Urology</i> , 2003, 169, 1643-1652.	0.4	112
128	Minimizing prostate brachytherapy-related morbidity. <i>Urology</i> , 2003, 62, 786-792.	1.0	72
129	The effect of interobserver differences in post-implant prostate CT image interpretation on dosimetric parameters. <i>Medical Physics</i> , 2003, 30, 1096-1102.	3.0	31
130	Extracapsular Radiation Dose Distribution After Permanent Prostate Brachytherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, e178-e189.	1.3	63
131	Biochemical Outcome for Hormone-Naïve Patients with High-Risk Prostate Cancer Managed with Permanent Interstitial Brachytherapy and Supplemental External-Beam Radiation. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 322-327.	2.0	17
132	177m-125 Versus Pd-103 for Low-Risk Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2002, 8, 69-73.	2.0	70
133	Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. <i>Urology</i> , 2002, 60, 104-108.	1.0	25
134	Biochemical outcome for hormone-naïve patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. <i>Urology</i> , 2002, 60, 98-103.	1.0	31
135	Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. <i>Urology</i> , 2002, 60, 650-655.	1.0	92
136	Biochemical outcome for hormone-naïve intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation. <i>Brachytherapy</i> , 2002, 1, 95-101.	0.5	20
137	Erectile function after permanent prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 893-902.	0.8	146
138	Clinical correlates of high intraprostatic brachytherapy dose volumes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 328-333.	0.8	13
139	Prostate-specific antigen spikes after permanent prostate brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 450-456.	0.8	85
140	The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 1055-1062.	0.8	110
141	The dosimetry of prostate brachytherapy-induced urethral strictures. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 461-468.	0.8	113
142	Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 664-673.	0.8	49
143	Prostate brachytherapy in obese patients. <i>Brachytherapy</i> , 2002, 1, 54-60.	0.5	13
144	Short-term sexual function after prostate brachytherapy. <i>International Journal of Cancer</i> , 2001, 96, 313-319.	5.1	81

#	ARTICLE	IF	CITATIONS
145	American Brachytherapy Society recommendations for clinical implementation of NIST-1999 standards for 103palladium brachytherapy. International Journal of Radiation Oncology Biology Physics, 2000, 47, 273-275.	0.8	80
146	Rectal function following prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2000, 48, 667-674.	0.8	60
147	Seed fixity in the prostate/periprostatic region following brachytherapy. International Journal of Radiation Oncology Biology Physics, 2000, 46, 215-220.	0.8	400
148	Isotope choice and the effect of edema on prostate brachytherapy dosimetry. Medical Physics, 2000, 27, 1067-1075.	3.0	24
149	Comparison of seed loading approaches in prostate brachytherapy. Medical Physics, 2000, 27, 381-392.	3.0	73
150	Rectal dosimetric analysis following prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 1999, 43, 1021-1027.	0.8	91
151	The dependence of prostate postimplant dosimetric quality on CT volume determination. International Journal of Radiation Oncology Biology Physics, 1999, 44, 1111-1117.	0.8	65
152	Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy. Radiation Oncology Investigations, 1998, 6, 182-190.	0.9	69
153	Prostatic conformal brachytherapy:125I/103Pd postoperative dosimetric analysis. Radiation Oncology Investigations, 1997, 5, 305-313.	0.9	23